Cancer vaccines represent a transformative frontier in oncology, offering the potential to elicit durable and specific immune responses against tumour-associated or tumour-specific antigens. This technology has the potential to treat established malignancy, reduce tumour relapse, and even prevent cancer formation—improving survival outcomes. Advances in neoantigen discovery, mRNA vaccine platforms, and personalised immunotherapy have substantially enhanced the feasibility and efficacy of…
[Perspectives] Current landscape, successes, and key challenges in cancer vaccine clinical trials across the UK
The Lancet Oncology | | Robert A Watson, Darcy Ward, Pippa Corrie, Elisa Fontana, William Ince, Victoria Kunene, Siow-Ming Lee, Mark Linch, Nangi Lo, Christian Ottensmeier, Miranda Payne, David Pinato, Thomas Powles, Elizabeth Smyth, Stefan N Symeonides, Fiona Thistlethwaite, Ojas Rajkumar, Henry Li, Lennard Lee
Topics: blood-cancer, cervical-cancer, immunotherapy, clinical-trials, research